FPS
LKFT

Fieldpoint Private Securities’s Lakefront Biotherapeutics American Depositary Shares LKFT Stock Holding History

Fieldpoint Private Securities’s Portfolio LKFT Stock Details LKFT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-5
Closed – – 1582
2021
Q1 		$0 Hold
5
– – ﹤0.01% 1587
2020
Q4 		$0 Buy
+5
New +$611 ﹤0.01% 1506

Other funds holding LKFT

Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Fieldpoint Private Securities's LKFT Position: Q2 2021 in Review

Fieldpoint Private Securities sold out of Lakefront Biotherapeutics American Depositary Shares (LKFT) in Q2 2021, closing a stake of 5 shares.

Fieldpoint Private Securities first reported a position in LKFT in Q4 2020 and held it in 2 quarters. The position peaked at $0 in Q1 2021. 108 funds tracked by Wall St. Rank hold LKFT as of Q2 2021.

  • Fieldpoint Private Securities reported no remaining Lakefront Biotherapeutics American Depositary Shares position as of Q2 2021 after selling out during the quarter.
  • Fieldpoint Private Securities sold 5 Lakefront Biotherapeutics American Depositary Shares shares in Q2 2021.
  • Fieldpoint Private Securities first reported a position in Lakefront Biotherapeutics American Depositary Shares in Q4 2020 and held it in 2 quarters.
  • Fieldpoint Private Securities's Lakefront Biotherapeutics American Depositary Shares position peaked at $0 in Q1 2021.
  • 108 funds tracked by Wall St. Rank held Lakefront Biotherapeutics American Depositary Shares as of Q2 2021.

Based on Fieldpoint Private Securities's 13F filing for Q2 2021, filed 12 Aug 2021.